Teva presents positive olanzapine LAI and UZEDY analyses for Medincell
Medincell said partner Teva presented new analyses for investigational olanzapine LAI showing 56% stabilization, 4% relapse post-stabilization, and 21% remission ≥6 months. Medincell also said UZEDY showed favorable continuity and lower HCRU versus once-monthly paliperidone. FDA PDUFA is expected in Q4 2026.